On February 29, 2024, Ionis Pharmaceuticals, Inc. announced Kyle Jenné has rejoined Ionis as executive vice president, commercial, to lead all aspects of commercialization at the Company. In addition, the Company announced Onaiza Cadoret-Manier, executive vice president, chief global product strategy and operations officer, is leaving the company to pursue another opportunity. To support the transition, Ms. Cadoret-Manier will remain in a full-time capacity through March 15, 2024, after which she will serve as an advisor to the Company for a period of time.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.59 USD | -0.60% | +2.24% | -17.79% |
Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 10 | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.79% | 6.07B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc. Announces Executive Changes